The Johns Hopkins Psilocybin Research: What the Studies Actually Found
Johns Hopkins has conducted more psilocybin research than any other institution in the world. Here's a plain-language breakdown of their major findings across depression, addiction, and end-of-life anxiety.
Johns Hopkins University has conducted more psilocybin research than any other institution in the world. Their Center for Psychedelic and Consciousness Research, established in 2019, is the first such center at a major academic medical institution in the United States.
Here is a plain-language breakdown of their major findings.
The 2006 Landmark Study
The modern era of psilocybin research began with a 2006 study by Roland Griffiths and colleagues, published in Psychopharmacology. This was the first rigorously controlled study of psilocybin in healthy volunteers in decades.
What they found: A single high dose of psilocybin produced mystical-type experiences that participants rated as among the most meaningful of their lives. At 14-month follow-up, 67% of participants rated the experience as one of the five most spiritually significant of their lives. Positive mood, life satisfaction, and altruistic behavior all increased.
Why it mattered: This study re-established the scientific legitimacy of psilocybin research after 30 years of prohibition. It provided the safety and methodology foundation for subsequent therapeutic trials.
The 2014 Smoking Cessation Study
Lead researcher: Matthew Johnson
Published in: Psychopharmacology
Enrolled: 15 smokers who had failed multiple previous quit attempts
What they found: 80% of participants were abstinent at 6-month follow-up. 67% remained abstinent at 12-month follow-up. For comparison, varenicline (Chantix) — the best available pharmaceutical — achieves approximately 35% abstinence at 6 months.
Why it mattered: This was the most impressive smoking cessation result in the scientific literature. It demonstrated that psilocybin could produce durable behavioral change in addiction.
The 2016 End-of-Life Anxiety Study
Lead researcher: Roland Griffiths
Published in: Journal of Psychopharmacology (simultaneously with NYU trial)
Enrolled: 51 cancer patients with life-threatening diagnoses
What they found: At 6-month follow-up, 78% of psilocybin participants showed clinically significant decreases in depressed mood and 83% showed decreases in anxiety. The effects were substantially larger than those produced by any existing pharmacological treatment for cancer-related anxiety.
The 2021 Major Depression RCT
Lead researcher: Alan Davis
Published in: JAMA Psychiatry
Enrolled: 24 adults with major depressive disorder (not treatment-resistant)
Design: Randomized controlled trial
What they found: 71% of participants showed a significant response. 54% met criteria for full remission. Effects maintained at 1-year follow-up in 75% of responders.
Why it mattered: Previous psilocybin depression trials focused on treatment-resistant depression. This trial showed psilocybin works for major depression broadly — not just the most severe cases.
What the Research Pipeline Looks Like
Johns Hopkins currently has active trials investigating psilocybin for:
This article is for informational purposes only and does not constitute medical advice.
This article is for informational purposes only and does not constitute medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your physician before making any changes to your health regimen.